Carson Seeber
Family Medicine · Clarkston, WANPI 1861740300
Payments from drug & device makers
Across 84 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$299
- Pfizer$189
- Boehringer Ingelheim$157
- GSK$151
- Tandem Diabetes Care, Inc.$83
- Merck$67
- plus $586 from 20 others
What the payments were for
- Food & beverage$1,49598%
- Education$372%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $299 |
| Pfizer | 17 | $189 |
| Boehringer Ingelheim | 10 | $157 |
| GSK | 7 | $151 |
| Tandem Diabetes Care, Inc. | 2 | $83 |
| Merck | 3 | $67 |
| Exact Sciences | 2 | $61 |
| AbbVie | 3 | $53 |
| Neurocrine Biosciences, Inc. | 2 | $50 |
| Johnson & Johnson | 2 | $44 |
| Bayer | 2 | $42 |
| Sanofi Pasteur Inc. | 1 | $40 |
| Amgen | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Novo Nordisk | 2 | $26 |
| Lilly USA, LLC | 2 | $23 |
| Dexcom, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Medtronic | 1 | $17 |
| Organogenesis Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$100
How this compares
$1,532 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 130 | $123,790 |
| OzempicSemaglutide | 110 | $107,821 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $41,037 |
| JanuviaSitagliptin Phosphate | 29 | $29,250 |
| MyrbetriqMirabegron | 16 | $16,123 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $14,043 |
| TrulicityDulaglutide | 14 | $13,460 |
| FarxigaDapagliflozin Propanediol | 17 | $12,964 |
| JardianceEmpagliflozin | 12 | $12,503 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $12,444 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $12,153 |
| XareltoRivaroxaban | 20 | $12,021 |
| MounjaroTirzepatide | 11 | $11,663 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $10,282 |
| TradjentaLinagliptin | 11 | $9,710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $189 | $123,790130 claims |
| Novo NordiskOzempic | $26 | $107,821110 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $151 | $65,633101 claims |
| MerckJanuvia | $67 | $29,25029 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $157 | $28,91037 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $23 | $25,12325 claims |
| AstraZenecaFarxiga, Pulmicort Flexhaler | $299 | $16,43631 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $16,12316 claims |
| Johnson & JohnsonXarelto | $44 | $12,02120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Clarkston
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
- Kevin HatfieldSeattle$527K
- Steven SmithAuburn$438K
- John RobinsonEdmonds$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.